A neurologist grapples with aducanumab
I have been following the controversy surrounding the approval of the new Alzheimer’s drug aducanumab with great interest. Until a year and a half ago, I worked as a neurologist in an adult general neurology clinic. Many of my patients had dementia. While I thoroughly enjoyed seeing these patients and their family members, I often felt helpless when treating them. When I left clinical practice to explore a non-clinical career …